作者
Gurkirpal Singh, John G Fort, Jay L Goldstein, Roger A Levy, Patrick S Hanrahan, Alfonso E Bello, Lilia Andrade-Ortega, Carl Wallemark, Naurang M Agrawal, Glenn M Eisen, William F Stenson, George Triadafilopoulos, SUCCESS-I Investigators
发表日期
2006/3/1
期刊
The American journal of medicine
卷号
119
期号
3
页码范围
255-266
出版商
Elsevier
简介
PURPOSE
To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis.
METHODS
A total of 13274 osteoarthritis patients from 39 countries were randomly assigned to double-blind treatment with either celecoxib 100 mg twice daily (BID), celecoxib 200 mg BID, or nonselective NSAID therapy (diclofenac 50 mg BID or naproxen 500 mg BID) for 12 weeks. Standard validated measures were used to assess osteoarthritis efficacy. Serious UGI events were evaluated by 2 blinded, independent, gastrointestinal events committees.
RESULTS
Results from all primary efficacy assessments showed that both dosages of celecoxib were as effective as NSAIDs in treating osteoarthritis. Significantly more ulcer complications occurred within the nonselective NSAID group (0.8/100 patient-years) compared …
引用总数
学术搜索中的文章
G Singh, JG Fort, JL Goldstein, RA Levy, PS Hanrahan… - The American journal of medicine, 2006